| |
Infliximab (IFX) |
Adalimumab (ADA) |
Ustekinumab (UST) |
| Number of patients |
46 |
36 |
52 |
| Age, years (mean ± SD) |
22-74 (48.6 ± 12.1) |
22-77 (51.2 ± 13.8) |
24-88 (60.1 ± 16.7)* |
| Gender (Male:Female) |
38:8 |
25:11 |
41:11 |
| Psoriasis type(PsV:PsA) |
38:8 |
26:10 |
49:2* |
| BMI (mean ± SD) |
18.4-34.9 (24.6 ± 4.1) |
18.4-34.9 (24.6 ± 4.1) |
18.4-34.3(24.3 ± 3.6) |
| PASI score (base line) |
10.2-65.0 (21.2 ± 12.7) |
10.0-54.0(19.1 ± 9.7) |
10.1-33.6(16.3 ± 6.0) |
| PASI score (end point) |
0.0-16.0 (2.0 ± 2.9) |
0.0-31.2(8.5 ± 9.6) |
0-20.0(2.3 ± 3.3) |
| Improvement of PASI |
90.2 ± 14.0% |
77.3 ± 24.7% |
85.7 ± 21.1 |
| PASI-75 |
42/46(91.3%) |
25/35(71.4%) |
44/52(84.6%) |
| IFX-appropriates (n) |
13 |
10 |
10 |
| ADA-appropriates (n) |
18 |
12 |
14 |
| UST-appropriates (n) |
15 |
14 |
28 |
| *Significant differences in terms of age and type of psoriasis were observed |
|
